Novartis: Kisqali effective over the long term, according to data

(CercleFinance.com) - On Tuesday, Novartis presented new data on the long-term efficacy of Kisqali in the treatment of early-stage breast cancer.


According to these results from the follow-up of a phase III study, Kisqali reduced distant recurrence by 28.5% in patients with stage 2 and 3 RH+/HER2- breast cancer, compared with conventional endocrine therapy (hormone treatment).

In a press release, Novartis cites "encouraging" data following the drug's recent US and European approvals in the treatment of early-stage breast cancer.

Breast cancer is characterized by the risk of recurrence after an initial diagnosis, often in metastatic form, i.e. spreading to other parts of the body.

Copyright (c) 2024 CercleFinance.com. All rights reserved.